11.14 -0.49 (-4.21%)

34.35% Fall from 52W High

65,836 XNAS Volume

XNAS 21 Apr, 2025 12:15 PM (EDT)

Low Financial Strength
16.7 / 100
Expensive Valuation
6.2 / 100
Technically Neutral
55.1 / 100
Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

Delcath Systems Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Chart titleHighcharts.com

Consensus Recommendation

Created with Highcharts 7.2.22Buy4Strong Buy
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Delcath Systems Inc Stock Analysis

Delcath Systems Inc stock analysis with key metrics, changes, and trends.

Delcath Systems Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$37.2 M1701.69%positive

Annual Revenue rose 1,701.69%, in the last year to $37.2 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

Annual Net Profit$26.39 M44.66%positive

Annual Net Profit rose 44.66% in the last year to $26.39 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

Price to Earning Ratio-14.12-negative

Price to Earning Ratio is -14.12, which is negative.

Stock Price$11.14128.75%positive

Stock Price rose 128.75% and outperformed its sector by 123.58% in the past year.

Quarterly Revenue$15.1 M2701.48%positive

Quarterly Revenue rose 2,701.48% YoY to $15.1 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit$3.4 M69.49%positive

Quarterly Net profit rose 69.49% YoY to $3.4 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

Debt to Equity Ratio0.02-positive

Debt to Equity Ratio of 0.02 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-62.44 %-62.44%negative

Return on Equity(ROE) for the last financial year was -62.44%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding11.43 %1.63%positive

Mutual Fund Holding increased by 1.63% in the last quarter to 11.43.

Promoter Share Holding12.17 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 12.17%.

Institutional Holding41.43 %0%negative

Institutional Holding decreased by 0% in the last quarter to 41.43.

VIEW LESS


Loading data..

Delcath Systems Inc - Company Profile

What does Delcath Systems Inc do?

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Delcath Systems Inc Management structure

All Gross Remunerations are in USD
Mr. Gerard J. Michel
Director and Chief Executive Officer
2.16 M
2024
Gross Remuneration
Year
Dr. Vojislav Vukovic, M.D.,PhD
Chief Medical Officer
1.09 M
2024
Gross Remuneration
Year
Dr. Martha S. Rook, PhD
Chief Operating Officer
933.1 K
2024
Gross Remuneration
Year
Mr. John Purpura, M.S.
Chief Operating Officer
-
2024
Gross Remuneration
Year
Ms. Sandra Pennell
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Johnny John, M.D.
Senior Vice President, Clinical Development and Medical Affairs
-
2024
Gross Remuneration
Year

Delcath Systems Inc Board of directors

All Gross Remunerations are in USD
Mr. John Richard Sylvester
Chairman of the Board
229.17 K
2024
Gross Remuneration
Year
Ms. Elizabeth A. Czerepak
Independent Director
205.67 K
2024
Gross Remuneration
Year
Mr. Steven Salamon
Independent Director
204.13 K
2024
Gross Remuneration
Year
Dr. Gilad Aharon, PhD
Independent Director
192.2 K
2024
Gross Remuneration
Year
Dr. Bridget Martell, M.A.,M.D.
Independent Director
176.25 K
2024
Gross Remuneration
Year
Dr. Roger G. Stoll,PhD
Independent Director
23.96 K
2024
Gross Remuneration
Year

Delcath Systems Inc FAQ

How is Delcath Systems Inc today?
Delcath Systems Inc today is trading in the red, and is down by -4.21% at 11.14.
Delcath Systems Inc is currently trading down -4.21% on an intraday basis. In the past week the stock rose 4.50%. stock has been down -22.15% in the past quarter and rose 128.75% in the past year. You can view this in the overview section.